Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fructooligosaccharide + lactiplantibacillus plantarum
- Development stage
- Preclinical
- Lead developer
- Nanchang University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A synbiotic combination composed of the probiotic bacterium *Lactiplantibacillus plantarum* (Lp) and the prebiotic fructooligosaccharide (FOS). This formulation is being investigated as a live biotherapeutic product for the treatment of food allergies, specifically soybean-induced allergies. Administered orally, the synbiotic works by modulating the gut microbiota—increasing the abundance of *Lachnospiraceae* and *Lactobacillus*—and restoring immune homeostasis. Preclinical studies have shown that the Lp-FOS intervention reduces levels of allergy-related immunoglobulins (IgE and IgG1), balances Th1/Th2 and Treg/Th17 cell populations, and improves intestinal barrier function. Additionally, it addresses metabolic dysregulation in the gut, particularly involving amino acid and tryptophan metabolism. Research is currently led by academic institutions such as Nanchang University.
- Other names
- Lp-FOSLactiplantibacillus plantarum and fructooligosaccharide synbiotic
Beyond the preview
Go deeper on fructooligosaccharide + lactiplantibacillus plantarum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fructooligosaccharide + lactiplantibacillus plantarum.